AstraZeneca COVID-19 Vaccine Trial Volunteer Showed Symptoms Of Rare Neurological Disorder

AstraZeneca Plc (NYSE: AZN) CEO Pascal Soriot said during a conference call with investors Wednesday that a person experiencing symptoms related to a rare neurological disorder caused its global COVID-19 vaccine trials to pause, Stat reported. What Happened: Soriot revealed that the trial participant, a woman in the United Kingdom, suffered symptoms consistent with a spinal inflammatory disorder called transverse myelitis, according to Stat.The diagnosis wasn’t confirmed and the woman could to be discharged from the hospital as soon as Wednesday, according to the executive.A board overseeing safety and data components of the trial reportedly confirmed that the participant was …read more

Source:: Yahoo Finance

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.